Immune & Antimicrobial
Bactericidal/Permeability-Increasing Protein (BPI)
In Gram-negative sepsis two things do the killing: the bacterium, and the endotoxin shed from its surface that drives the inflammation collapsing the circulation. Bactericidal/permeability-increasing protein, stored in the granules of neutrophils, the white blood cells that reach an infection first, handles both at once — it grips endotoxin tightly and punctures the bacterium at the same time. A recombinant fragment, rBPI21, was tested on exactly that logic in 393 children with severe meningococcal sepsis and could not prove it: deaths were 7.4% on the drug against 9.9% on placebo, a gap too small to be statistically meaningful, partly because far fewer placebo children died than the trial had been built to expect. No regulator has approved it.
Last updated
Mechanism
Binds lipopolysaccharide with high affinity, permeabilising Gram-negative outer membranes and blocking endotoxin-driven inflammatory signalling.
Reported effects
What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.
- Gram-negative bactericidal research
- Endotoxin neutralisation research
- Sepsis research context
Dosing on file unverified
rBPI21: Phase I/II/III trials; dosing variable by study; well-tolerated
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Literature on file 3
-
human observational
NCT00462904: Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury graded on: a registered clinical study — “clinicaltrials.gov”
-
human RCT
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial (The Lancet 2000, cited 333x) graded on: a randomised trial — “randomised trial”
-
human RCT
Bactericidal/permeability-increasing protein—Lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia (Critical Care Medicine 2001, cited 71x) graded on: a randomised trial — “randomized, clinical trial”
Identity
- UniProt
- P17213
Notes unverified prose
Phase I/II/III completed (meningococcemia, trauma); rBPI21; NCT00462904; rBPI21 Phase I/II/III; Phase III meningococcemia
Not on file 9
8 of the 8 fields we track hold nothing on this record, and each says why. 1 further absence is named below. A blank field is a bug; a named absence is a finding.
- molecular weightnothing we hold supplies it
- molecular formulanothing we hold supplies it
- CAS registry numbernothing we hold supplies it
- PubChem identifiernothing we hold supplies it
- amino-acid sequencenothing we hold supplies it
- SMILES stringnothing we hold supplies it
- InChInothing we hold supplies it
- InChI keynothing we hold supplies it
- half-lifenothing we hold supplies it
Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.